ABSTRACT
Current immunosuppressive/anti-inflammatory agents target the responding effector arm of the immune response and their nonspecific action increases the risk of infection and malignancy. These effects impact on their use in allogeneic haematopoietic cell transplantation and other forms of transplantation. Interventions that target activated dendritic cells (DCs) have the potential to suppress the induction of undesired immune responses (for example, graft versus host disease (GVHD) or transplant rejection) and to leave protective T-cell immune responses intact (for example, cytomegalovirus (CMV) immunity). We developed a human IgG1 monoclonal antibody (mAb), 3C12, specific for CD83, which is expressed on activated but not resting DC. The 3C12 mAb and an affinity improved version, 3C12C, depleted CD83(+) cells by CD16(+) NK cell-mediated antibody-dependent cellular cytotoxicity, and inhibited allogeneic T-cell proliferation in vitro. A single dose of 3C12C prevented human peripheral blood mononuclear cell-induced acute GVHD in SCID mouse recipients. The mAb 3C12C depleted CMRF-44(+)CD83(bright) activated DC but spared CD83(dim/-) DC in vivo. It reduced human T-cell activation in vivo and maintained the proportion of CD4(+) FoxP3(+) CD25(+) Treg cells and also viral-specific CD8(+) T cells. The anti-CD83 mAb, 3C12C, merits further evaluation as a new immunosuppressive agent in transplantation.
Subject(s)
Antibodies, Monoclonal/pharmacology , Dendritic Cells/drug effects , Graft Rejection/prevention & control , Graft vs Host Disease/prevention & control , Immunosuppressive Agents/pharmacology , Membrane Glycoproteins/antagonists & inhibitors , Animals , Antigens, CD/genetics , Antigens, CD/immunology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Cell Proliferation/drug effects , Cytotoxicity, Immunologic/drug effects , Dendritic Cells/immunology , Dendritic Cells/pathology , Female , Gene Expression , Graft Rejection/immunology , Graft Rejection/mortality , Graft Rejection/pathology , Graft vs Host Disease/immunology , Graft vs Host Disease/mortality , Graft vs Host Disease/pathology , Humans , Immunoglobulins/genetics , Immunoglobulins/immunology , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Killer Cells, Natural/pathology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/transplantation , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Mice , Mice, SCID , Survival Analysis , Transplantation, Heterologous , CD83 AntigenABSTRACT
Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio-process to purify CMRF-56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF-56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
Subject(s)
Cancer Vaccines/therapeutic use , Dendritic Cells/transplantation , Multiple Myeloma/therapy , Antibodies, Monoclonal/isolation & purification , Antigen Presentation/immunology , Antigens, Differentiation/immunology , Antigens, Neoplasm/immunology , Biotinylation , Cells, Cultured , Cytotoxicity, Immunologic , Humans , Immunomagnetic Separation/methods , Leukapheresis , Multiple Myeloma/immunology , T-Lymphocytes, Cytotoxic/immunology , Vaccination/methodsABSTRACT
Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34(+) cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c(+)CD16() CD1a()/c() MDCs from CB CD34(+) cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33(+)CD14()CD15() precursors with a mean of 4 x 10(6) cells generated from 1-4 x 10(4) CB CD34(+) cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34(+) cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.
Subject(s)
Antigens, CD34/metabolism , Dendritic Cells/cytology , Fetal Blood/cytology , Interleukins/pharmacology , Membrane Proteins/pharmacology , Myeloid Cells/cytology , Stem Cell Factor/pharmacology , Antigens, CD1/metabolism , CD11c Antigen/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Dendritic Cells/drug effects , Fetal Blood/drug effects , Humans , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Myeloid Cells/drug effects , Phenotype , Stem Cells/cytology , Stem Cells/drug effects , T-Lymphocytes/cytology , T-Lymphocytes/drug effectsABSTRACT
This review describes and compares the different DC preparations currently under laboratory and clinical investigation as vehicles for cancer immunotherapy.
Subject(s)
Cell Separation , Dendritic Cells/immunology , Hematopoietic Stem Cells/immunology , Immunization, Passive , Immunotherapy , Monocytes/immunology , Antigens, CD/immunology , Cell Culture Techniques/methods , Cell Differentiation/drug effects , Cell Differentiation/immunology , Cell Division/immunology , Cells, Cultured , Cytokines/immunology , Cytokines/pharmacology , Dendritic Cells/transplantation , Humans , Lymphocyte Activation/immunology , T-Lymphocytes, Cytotoxic/immunology , VaccinesABSTRACT
Understanding the biology of the DC and its pivotal role in immune response initiation and regulation has enabled new effective anti-cancer therapies to be developed for treatment of a wide range of tumor types. Many studies on DC-based cancer vaccine development have focused on the development of methods that can effectively deliver tumor Ags to DCs. Numerous methods have been developed or evaluated for the delivery of defined and undefined tumor Ags to DCs for processing and presentation to T lymphocytes. This review provides a brief summary of these methods, the techniques that are used in each, how they have -- or could -- be applied clinically, as well as the advantages and disadvantages of each method.
Subject(s)
Antigen Presentation/immunology , Antigens, Neoplasm/immunology , Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Dendritic Cells/transplantation , Neoplasms/therapy , Adoptive Transfer , Animals , Antigen Presentation/genetics , Antigens, CD/immunology , Antigens, Neoplasm/genetics , Cancer Vaccines/immunology , Cell Culture Techniques/methods , Cytokines/immunology , DNA, Neoplasm/genetics , DNA, Neoplasm/immunology , Histocompatibility Antigens/immunology , Humans , Lymphocyte Activation/immunology , Mice , Neoplasms/immunology , Peptides/immunology , Proteins/immunology , RNA, Neoplasm/immunology , Receptors, Cell Surface/immunology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , T-Lymphocytes/immunology , VaccinationABSTRACT
Therapy for patients with multiple myeloma (MM) is currently unsatisfactory and most patients eventually succumb to relapsed disease. DCs are a subset of leukocytes with the capacity to initiate and control the adaptive immune response against many cancers, including MM. In MM patients, in vivo DC function is often abnormal, however, it appears that it can be restored by in vitro manipulation. This has led to the development of DC immunotherapy for MM patients. We review the background research leading to the recognition of an anti-MM immune response, and discuss abnormalities in DC function, potential tumor-associated Ags, and the results of clinical trials of DC immunotherapy in MM patients.
Subject(s)
Cancer Vaccines/therapeutic use , Dendritic Cells/pathology , Dendritic Cells/transplantation , Immunotherapy, Adoptive/methods , Multiple Myeloma/pathology , Multiple Myeloma/therapy , Antigen Presentation/immunology , Antigens, CD/immunology , Antigens, Neoplasm/immunology , Cell Culture Techniques/methods , Cell Separation/methods , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Cytokines/immunology , Dendritic Cells/immunology , Hematopoiesis/immunology , Humans , Multiple Myeloma/immunology , T-Lymphocytes/immunology , T-Lymphocytes/pathologyABSTRACT
The long-held belief that breast cancer is a weakly immunogenic tumor and a poor candidate for immunotherapy should be reappraised. There is ample evidence for the existence of an immune response, which is, however, attenuated by multiple inhibitory factors. Many tumor-associated antigens (TAA) have been identified in breast cancer, some of which appear to play a critical role in tumorigenesis and may be attractive targets for immunotherapy. There is evidence for DC recruitment and activation within breast cancers, and the presence of intratumoral activated DCs impacts favorably upon survival. Furthermore, there is a striking paucity of activated DCs within the primary draining or sentinel lymph nodes of breast cancers. Tumor infiltrating lymphocytes (TIL) are often documented, however, their function is impaired by inhibitory cytokines, increased regulatory T lymphocyte activity, tumor cell MHC molecule alterations, and aberrant Fas ligand expression, amongst others. DCs are recognized as one of the critical interfaces between a cancer and the immune system, and have emerged as a promising platform for cancer vaccination via ex vivo immunomodulation. Clinical evaluation of DC vaccination in breast cancer is still relatively limited, although evolving. This article details evidence for the immune response in breast cancer and its many failings, and reviews the clinical trials and significant preclinical data which, taken together, validate the concept of DC vaccination in breast cancer.
Subject(s)
Breast Neoplasms/immunology , Breast Neoplasms/therapy , Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Dendritic Cells/transplantation , Immunotherapy, Adoptive , Adenoviridae/genetics , Adenoviridae/immunology , Animals , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , DNA, Neoplasm/genetics , DNA, Neoplasm/immunology , Female , Humans , Immunologic Memory , Mice , Peptides/immunology , Proteins/immunology , RNA, Neoplasm/genetics , RNA, Neoplasm/immunology , T-Lymphocytes/immunologyABSTRACT
Despite rapid advances in cancer therapeutics, relapsed disease due to failed immunosurveillance remains a major problem in many cancers. Dendritic cells are recognized as key to the induction of immune responses to cancer and intensive study is underway to facilitate their use in cancer immunotherapy. In initial clinical trials, dendritic cell preparations were, with the benefit of hindsight, largely sub-optimal, yet encouraging results have been seen. The challenge now is to expand our knowledge of the interactions between tumors and the immune system, through basic scientific research and coordinated large-scale clinical studies. This review focuses on the anti-tumor immune response, human dendritic cell biology and the results of recent clinical studies of dendritic cell immunotherapy for cancer.
Subject(s)
Dendritic Cells/immunology , Immunotherapy/methods , Neoplasms/immunology , Neoplasms/therapy , Cancer Vaccines/immunology , Clinical Trials as Topic , Dendritic Cells/physiology , Humans , Immunity, Innate , T-Lymphocytes/immunologyABSTRACT
Dendritic cells (DC) from distinct DC subsets are essential contributors to normal human immune responses. Despite this, reliable assays that enable DC to be counted precisely have been slow to evolve. We have now developed a new single-platform flow cytometric assay based on TruCOUNT beads and the whole blood "Lyse/No-Wash" protocol that allows precise counting of the CD14(-) blood DC subsets: CD11c(+)CD16(-) DC, CD11c(+)CD16(+) DC, CD123(hi) DC, CD1c(+) DC and BDCA-3(+) DC. This assay requires 50 microl of whole blood; does not rely on a hematology blood analyser for the absolute DC counts; allows DC counting in EDTA samples 24 h after collection; and is suitable for cord blood and peripheral blood. The data is highly reproducible with intra-assay and inter-assay coefficients of variation less than 3% and 11%, respectively. This assay does not produce the DC-T lymphocyte conjugates that result in DC counting abnormalities in conventional gradient-density separation procedures. Using the TruCOUNT assay, we established that absolute blood DC counts reduce with age in healthy individuals. In preliminary studies, we found a significantly lower absolute blood CD11c(+)CD16(+) DC count in stage III/IV versus stage I/II breast carcinoma patients and a lower absolute blood CD123(hi) DC count in multiple myeloma patients, compared to age-matched controls. These data indicate that scientific progress in DC counting technology will lead to the global standardization of DC counting and allow clinically meaningful data to be obtained.
Subject(s)
Dendritic Cells/immunology , Flow Cytometry/methods , Adult , Aged , Blood Cell Count/methods , Breast Neoplasms/blood , Centrifugation, Density Gradient , Dendritic Cells/cytology , Female , Humans , Immunophenotyping , Male , Microspheres , Middle Aged , Multiple Myeloma/blood , Reproducibility of ResultsABSTRACT
T cells are present in the inflammatory infiltrates of periodontal disease lesions and require antigen presentation by antigen-presenting cells (APCs). While it is still not known whether Th1 or Th2 cells predominate in these lesions, it has been reported that different APCs may induce activation of different T-cell subsets. An immunoperoxidase technique was used to investigate the presence of CD1a+, CMRF-44+, CMRF-58+ and CD83+ dendritic cells, CD14+ macrophages or dendritic cell precursors and CD19+ B cells in gingival biopsies from 21 healthy or gingivitis and 25 periodontitis subjects. The samples were divided into three groups according to the size of infiltrate (group 1, small infiltrates; group 2, medium infiltrates; group 3, extensive infiltrates). The presence of numerous CD1a+ Langerhans cells was noted in the epithelium with no differences between the healthy/gingivitis and periodontitis groups. The percentage of CD83+ dendritic cells in the infiltrates was higher than the percentage of CD1a+, CMRF-44+ or CMRF-58+ dendritic cells. Endothelial cells positive for CD83 were found predominantly in areas adjacent to infiltrating cells, CD83+ dendritic cells being noted in the region of CD83+ endothelium. The percentage of CD14+ cells in the inflammatory infiltrates was similar to that of CD83+ dendritic cells. B cells were the predominant APC in group 2 and 3 tissues. The percentage of B cells in group 3 periodontitis lesions was increased in comparison with group 1 periodontitis tissues and also in comparison with group 3 healthy/gingivitis sections. Functional studies are required to determine the roles of different APC subpopulations in periodontal disease.
Subject(s)
Antigen-Presenting Cells/classification , Periodontitis/immunology , Antigen Presentation/immunology , Antigen-Presenting Cells/immunology , Antigens, CD/analysis , Antigens, CD1/analysis , Antigens, CD19/analysis , Antigens, Differentiation/analysis , B-Lymphocytes/classification , B-Lymphocytes/immunology , Dendritic Cells/classification , Dendritic Cells/immunology , Endothelium/immunology , Epithelium/immunology , Gingiva/immunology , Gingivitis/immunology , Humans , Immunoenzyme Techniques , Immunoglobulins/analysis , Langerhans Cells/classification , Langerhans Cells/immunology , Linear Models , Lipopolysaccharide Receptors/analysis , Macrophages/classification , Macrophages/immunology , Membrane Glycoproteins/analysis , Multivariate Analysis , Periodontitis/pathology , Statistics as Topic , T-Lymphocyte Subsets/immunology , CD83 AntigenSubject(s)
Antigens, Surface , Membrane Glycoproteins , Amino Acid Sequence , Animals , Antigens, Surface/chemistry , Antigens, Surface/genetics , Antigens, Surface/metabolism , Epitopes , Humans , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Mice , Molecular Sequence Data , Sequence Homology, Amino Acid , Signal Transduction , Tissue DistributionABSTRACT
The MUC1 mucin (CD227) is a cell surface mucin originally thought to be restricted to epithelial tissues. We report that CD227 is expressed on human blood dendritic cells (DC) and monocyte-derived DC following in vitro activation. Freshly isolated murine splenic DC had very low levels of CD227; however, all DC expressed CD227 following in vitro culture. In the mouse spleen, CD227 was seen on clusters within the red pulp and surrounding the marginal zone in the white pulp. Additionally, we confirm CD227 expression by activated human T cells and show for the first time that the CD227 cytoplasmic domain is tyrosine-phosphorylated in activated T cells and DC and is associated with other phosphoproteins, indicating a role in signaling. The function of CD227 on DC and T cells requires further elucidation.
Subject(s)
Dendritic Cells/immunology , Mucin-1/immunology , Animals , B-Lymphocytes/cytology , B-Lymphocytes/immunology , CD11c Antigen/immunology , Cells, Cultured , Cytoplasm , Dendritic Cells/cytology , Humans , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Phosphorylation , Spleen/cytology , T-Lymphocytes/cytology , T-Lymphocytes/immunologyABSTRACT
PURPOSE: Prostate specific antigen (PSA) is found in high concentration in prostate tissue and in semen, in which its physiological function appears to be liquefaction. In prostate cancer the peripheral PSA concentration is elevated, which may be used as a disease marker. Systemic and local immune defects have been demonstrated in prostate cancer and we postulated a role for PSA in this immunosuppression. We explored the effects of PSA on human T-lymphocyte proliferation in vitro. MATERIALS AND METHODS: PSA was purified from normal seminal plasma using a modified chromatographic technique. The effect of PSA or control protein on lymphocyte responses to mitogens, tetanus toxoid and alloantigens was tested. The inhibitory effect observed was further explored by varying the time of PSA addition, denaturing PSA and including interleukin-2 and anti-PSA antibodies. RESULTS: PSA suppressed in vitro phytohemagglutinin and alloantigen stimulated lymphocyte proliferation in a dose dependent manner. This effect was reversed by adding anti-PSA antibodies but not by interleukin-2. CONCLUSIONS: These in vitro PSA effects suggest another T-lymphocyte mediated immunosuppressive mechanism. In vivo high levels of PSA may compromise natural immune responses to cancer and current attempts at immunotherapy for prostate cancer.
Subject(s)
Lymphocyte Activation/immunology , Prostate-Specific Antigen/physiology , Prostatic Neoplasms/immunology , T-Lymphocytes/immunology , Disease Progression , Humans , Immune Tolerance/immunology , Male , Tumor Escape/physiologyABSTRACT
Dendritic cells (DC) initiate tumor specific immune responses in animal studies and initial human trials suggest that certain tumor-antigen loaded DC preparations generate clinical responses. DC may be obtained from blood or generated in vitro from precursor cells. In vitro generation of DC from precursor cells, under the influence of cytokines, has been favoured to date as a source because of the greater numbers of DC produced. However, the different cytokine combinations and serum or plasma component(s) used, differentiate precursor cells into DC with different physiological properties and ultimate immunogenicity. Thus, the quality of in vitro cytokine derived DC may have a profound influence on clinical outcomes. The administration of certain growth factors, which increase the number of circulating blood DC, may provide an alternative source of DC for use in clinical trials. Although clinical trials in prostate cancer, melanoma and metastatic renal carcinoma patients are encouraging, some data suggest certain DC preparations and administration protocols are sub optimal, even potentially tumor enhancing. As basic scientific studies establish how to provide DC with stable phenotype, resistance to tumour inhibitory factors and high migratory capacity, the technology for producing cytokine derived DC in vitro using Good Manufacturing Practise (GMP) conditions needs to be developed. Future DC vaccination protocols will require careful control of the DC used for tumor-antigen loading and repetitive long term DC vaccination may be necessary to maintain effective anti-tumor immune responses.
Subject(s)
Cytokines/therapeutic use , Dendritic Cells/physiology , Growth Substances/therapeutic use , Animals , Antigens, CD34/immunology , Cell Differentiation , Clinical Trials as Topic , Dendritic Cells/immunology , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/cytology , Humans , Immunotherapy , Monocytes/cytology , Neoplasms/immunology , Neoplasms/therapyABSTRACT
Vaccines are one of the most cost effective methods of improving public health thereby increasing the quality of life. Prophylactic and therapeutic treatment by vaccines can prevent infectious diseases and some cancers and could also be used in the treatment of autoimmune disorders. An appreciation of this potential has resulted in a burgeoning literature which not only describes the scientific efforts being made into designing new and improved vaccines but also drives the efforts being made by public health organizations world-wide in delivering vaccines to the community. At the forefront of technologies being applied to the design of vaccines is the use of synthetic peptides; the chemical technologies used to assemble peptides have made great strides over the last decade and assembly of hi-fidelity peptides which can be of high molecular weight, multimeric or even branched is now almost routine. Together with the advances in peptide technology our understanding of the molecular events that are necessary to induce immune responses has also made great strides. The central role that peptides play in immune recognition is now recognised and rules are emerging that are being applied to the construction of peptide-based vaccines that, in the right context, can induce humoral (antibody) and cellular (cytotoxic and helper T cell) immune responses. Synthetic peptides are exquisitely placed to answer questions about immune recognition and along the way to provide us with new and improved vaccines.
Subject(s)
Communicable Diseases/drug therapy , Communicable Diseases/immunology , Neoplasms/drug therapy , Neoplasms/immunology , Peptides/physiology , Vaccines, Subunit/chemical synthesis , Vaccines, Subunit/immunology , Animals , Antibody Formation/drug effects , Drug Delivery Systems/methods , Humans , Immunity, Cellular/drug effects , Vaccines, Subunit/administration & dosageABSTRACT
Low CD1a-positive putative dendritic cell numbers in human breast cancer has recently been described and may explain the apparent 'poor immunogenicity' previously reported in breast cancer. Little attention has been given to dendritic cell activation within the tumour microenvironment, which is another reason why the in-situ immune response may be severely deficient. We have therefore examined CD1a expression as a marker for dendritic cells, together with CMRF-44 and -56 as markers of dendritic cell activation status, in 40 human breast cancers. The results demonstrate few or no CD1a-positive putative dendritic cells and minimal or no expression of the dendritic cell activation markers. Both dendritic cell number and dendritic cell activation appear substantially deficient in human breast cancers, regardless of tumour histological grade.
Subject(s)
Antigens, CD1/immunology , Antigens, Differentiation/immunology , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Dendritic Cells/pathology , Immunoglobulins/immunology , Membrane Glycoproteins/immunology , Antigens, CD , Breast Neoplasms/immunology , Carcinoma, Ductal, Breast/immunology , Cell Count , Dendritic Cells/immunology , Female , Fluorescent Antibody Technique , Humans , Immunoenzyme Techniques , Neoplasm Staging , CD83 AntigenABSTRACT
OBJECTIVE: Dendritic cells (DC) are the only antigen-presenting cells that can activate naïve T lymphocytes and initiate a primary immune response. They are also thought to have a role in immune tolerance. DC traffic from the blood to peripheral tissue where they become activated. They then present antigen and the costimulating signals necessary to initiate an immune response. In this study, we investigated the number, subsets, and activation pattern of circulating and intestinal DC from patients with clinically mild ulcerative colitis (UC) or Crohn's disease. METHODS: Patients were recruited, if they were not taking immunosuppressive therapy, and were assessed for clinical severity of their disease using for UC, the Clinical Activity Index, and for Crohn's disease, the Crohn's Disease Activity Index. Blood CD11c+ and CD11c- DC subsets, expression of costimulatory antigens, CD86 and CD40, and the early differentiation/activation antigen, CMRF44, were enumerated by multicolor flow cytometry of lineage negative (lin- = CD3-, CD19-, CD14-, CD16-) HLA-DR+ DC. These data were compared with age-matched healthy and the disease control groups of chronic noninflammatory GI diseases (cGI), acute noninflammatory GI diseases (aGI), and chronic non-GI inflammation (non-GI). In addition, cryostat sections of colonoscopic biopsies from healthy control patients and inflamed versus noninflamed gut mucosa of inflammatory bowel disease (IBD) patients were examined for CD86+ and CD40+ lin- cells. RESULTS: Twenty-one Crohn's disease and 25 UC patients, with mean Crohn's Disease Activity Index of 98 and Clinical Activity Index of 3.1, and 56 healthy controls, five cGI, five aGI, and six non-GI were studied. CD11c+ and CD11c- DC subsets did not differ significantly between Crohn's, UC, and healthy control groups. Expression of CD86 and CD40 on freshly isolated blood DC from Crohn's patients appeared higher (16.6%, 31%) and was significantly higher in UC (26.6%, 46.3%) versus healthy controls (5.5%, 25%) (p = 0.004, p = 0.012) and non-GI controls (10.2%, 22.8%) (p = 0.012, p = 0.008), but not versus cGI or aGI controls. CD86+ and CD40+ DC were also present in inflamed colonic and ileal mucosa from UC and Crohn's patients but not in noninflamed IBD mucosa or normal mucosa. Expression of the CMRF44 antigen was low on freshly isolated DC, but it was upregulated after 24-h culture on DC from all groups, although significantly less so on DC from UC versus Crohn's or healthy controls (p = 0.024). The CMRF44+ antigen was mainly associated with CD11c+ DC, and in UC was inversely related to the Clinical Activity Index (r = -0.69, p = 0.0002). CONCLUSIONS: There is upregulation of costimulatory molecules on blood DC even in very mild IBD but surprisingly, there is divergent expression of the differentiation/activation CMRF44 antigen. Upregulation of costimulatory molecules and divergent expression of CMRF44 in blood DC was also apparent in cGI and aGI but not in non-GI or healthy controls, whereas intestinal CD86+ and CD40+ DC were found only in inflamed mucosa from IBD patients. Persistent or distorted activation of blood DC or divergent regulation of costimulatory and activation antigens may have important implications for gut mucosal immunity and inflammation.
Subject(s)
Antigens, Differentiation/immunology , Dendritic Cells/immunology , Inflammatory Bowel Diseases/immunology , Adolescent , Adult , Aged , Antibodies, Monoclonal , Antigens, CD/immunology , Antigens, CD/physiology , Antigens, Differentiation/physiology , B7-2 Antigen , CD40 Antigens/immunology , CD40 Antigens/physiology , Female , Flow Cytometry , Fluorescent Antibody Technique , Humans , Inflammatory Bowel Diseases/blood , Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/physiopathology , Male , Membrane Glycoproteins/immunology , Membrane Glycoproteins/physiology , Middle Aged , Severity of Illness Index , Up-RegulationABSTRACT
The immunoregulatory signaling (IRS) family includes several molecules, which play major roles in the regulation of the immune response. The CMRF-35A and CMRF-35H molecules are two new members of the IRS family of molecules, that are found on a wide variety of haemopoietic lineages. The extracellular functional interactions of these molecules is presently unknown, although CMRF-35H can initiate an inhibitory signal and is internalized when cross-linked. In this paper, we described the gene structure for the CMRF-35A gene and its localization to human chromosome 17. The gene consists of four exons spanning approximately 4.5 kb. Exon 1 encodes the 5' untranslated region and leader sequence, exon 2 encodes the immunoglobulin (Ig)-like domain, exon 3 encodes the membrane proximal region and exon 4 encodes the transmembrane region, the cytoplasmic tail and the 3' untranslated region. A region in the 5' flanking sequence of the CMRF-35A gene, that promoted expression of a reporter gene was identified. The genes for the CMRF-35A and CMRF-35H molecules are closely linked on chromosome 17. Similarity between the Ig-like exons and the preceding intron of the two genes suggests exon duplication was involved in their evolution. We also identified a further member of the CMRF-35 family, the CMRF-35J pseudogene. This gene appears to have arisen by gene duplication of the CMRF-35A gene. These three loci - the CMRF-35A, CMRF-35J and CMRF-35H genes-form a new complex of IRS genes on chromosome 17.
Subject(s)
Antigens, Surface , Chromosomes, Human, Pair 17/genetics , Membrane Glycoproteins/genetics , Multigene Family/genetics , Signal Transduction/immunology , 3' Untranslated Regions/genetics , 5' Untranslated Regions/genetics , Amino Acid Sequence/genetics , Base Sequence/genetics , Chromosome Mapping , Humans , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/isolation & purification , Molecular Sequence Data , Pseudogenes/immunology , Tumor Cells, Cultured , U937 CellsABSTRACT
Heterogeneous expression of several antigens on the three currently defined tonsil dendritic cell (DC) subsets encouraged us to re-examine tonsil DCs using a new method that minimized DC differentiation and activation during their preparation. Three-color flow cytometry and dual-color immunohistology was used in conjunction with an extensive panel of antibodies to relevant DC-related antigens to analyze lin(-) HLA-DR(+) tonsil DCs. Here we identify, quantify, and locate five tonsil DC subsets based on their relative expression of the HLA-DR, CD11c, CD13, and CD123 antigens. In situ localization identified four of these DC subsets as distinct interdigitating DC populations. These included three new interdigitating DC subsets defined as HLA-DR(hi) CD11c(+) DCs, HLA-DR(mod) CD11c(+) CD13(+) DCs, and HLA-DR(mod) CD11c(-) CD123(-) DCs, as well as the plasmacytoid DCs (HLA-DR(mod) CD11c(-) CD123(+)). These subsets differed in their expression of DC-associated differentiation/activation antigens and co-stimulator molecules including CD83, CMRF-44, CMRF-56, 2-7, CD86, and 4-1BB ligand. The fifth HLA-DR(mod) CD11c(+) DC subset was identified as germinal center DCs, but contrary to previous reports they are redefined as lacking the CD13 antigen. The definition and extensive phenotypic analysis of these five DC subsets in human tonsil extends our understanding of the complexity of DC biology.
Subject(s)
Dendritic Cells/classification , Dendritic Cells/physiology , Palatine Tonsil/cytology , CD13 Antigens/metabolism , Flow Cytometry , HLA-DR Antigens/metabolism , Humans , Immunohistochemistry , Integrin alphaXbeta2/metabolism , Interleukin-3 Receptor alpha Subunit , Palatine Tonsil/metabolism , Phenotype , Receptors, Interleukin-3/metabolismABSTRACT
Dendritic cells (DCs) are specialized antigen-presenting cells that have the unique ability to initiate a primary immune response. The effect of physiologic stress on circulating blood DCs has thus far not been studied. In this study, we applied a recently developed method of counting blood DCs to test the hypothesis that significant stress to the body such as surgery and exercise might induce measurable changes in the DC numbers, subsets, phenotype, and function. Twenty-six patients scheduled for elective laparoscopic cholecystectomy, 4 for elective hysterectomy, 56 controls, and 5 volunteers who underwent a stress exercise test were enrolled in the study. Absolute DC counts increased acutely (71.7% +/- 11% [SEM], P =.0001) in response to the stress of surgery and dropped below preoperative levels (-25% +/- 14% [SEM], P =.05) on days 2-3. The perioperative DC subset balance remained constant. Interestingly, DC counts changed independently of monocyte counts. Exercise also induced a rise in DC counts but coincidentally with monocyte counts. Surprisingly, no phenotypic or functional activation of DCs was seen in either stress situations in vivo. DCs are rapidly mobilized into the circulation in response to surgical and exercise stress, which may serve to prepare the host's immune defenses against trauma. The independent regulation of the DC and monocyte counts reinforces the distinction between these 2 cell populations.